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Multiple sclerosis (MS) is the principal cause of autoimmune neuroinflammation in 
humans, and its animal model, experimental autoimmune encephalomyelitis (EAE), is 
widely used to gain insight about their immunopathological mechanisms for and the 
development of novel therapies for MS. Most studies on the role of interferon (IFN)-γ 
in the pathogenesis and progression of EAE have focused on peripheral immune cells, 
while its action on central nervous system (CNS)-resident cells has been less explored. 
In addition to the well-known proinflammatory and damaging effects of IFN-γ in the CNS, 
evidence has also endowed this cytokine both a protective and regulatory role in auto-
immune neuroinflammation. Recent investigations performed in this research field have 
exposed the complex role of IFN-γ in the CNS uncovering unexpected mechanisms of 
action that underlie these opposing activities on different CNS-resident cell types. The 
mechanisms behind these two-faced effects of IFN-γ depend on dose, disease phase, 
and cell development stage. Here, we will review and discuss the dual role of IFN-γ 
on CNS-resident cells in EAE highlighting its protective functions and the mechanisms 
proposed.
Keywords: interferon-gamma, experimental autoimmune encephalomyelitis, multiple sclerosis, glial cells, 
neurons, central nervous system, neuroinflammation
inTRODUCTiOn
Multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), 
are chronic autoimmune diseases of the central nervous system (CNS) characterized by inflammatory 
infiltrates, demyelination and neurological damage (1, 2). MS and EAE were initially considered to 
be mediated by interferon (IFN)-γ-expressing T helper (Th) 1 cells (3, 4). Currently, it is most widely 
accepted that several innate and adaptive immune cell types and immunomodulatory molecules 
contribute to the disease development and progression (5). Moreover, several studies have challenged 
the notion that IFN-γ is only pathogenic, and accumulative evidence attributes it a protective role in 
EAE and MS (6–8). In this same journal research topic, we have reviewed recent data supporting a 
stage-specific participation of IFN-γ in MS and EAE providing a plausible explanation for previous 
conflicting results and a model whereby this cytokine can both promote and limit the development of 
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these pathologies (8). However, the majority of these studies have 
focused on the roles of IFN-γ in immune cells, while its activity in 
CNS-resident cells remains less explored. In this review, we will 
begin by discussing evidence that reports opposite roles of IFN-γ 
in the CNS during EAE development. Then, we will review both 
the inflammatory and protective effects of IFN-γ on glial cells and 
neurons in EAE.
OPPOSinG eFFeCTS OF iFn-γ in THe 
CnS DURinG eAe
Early studies demonstrated that IFN-γ can activate CNS-resident 
cells and induce expression of major histocompatibility complex 
(MHC) molecules (3, 9). Direct injection of IFN-γ into the rat 
CNS induced inflammation and cellular infiltration similar to 
that observed in EAE (10–13) and potentiated the demyelination 
process (13). Furthermore, demyelination occurred in transgenic 
mice expressing IFN-γ under the control of the myelin basic 
protein (MBP) promoter (14–16). On the contrary, animals with 
EAE that were injected with IFN-γ systemically or directly into 
the CNS showed amelioration of clinical symptoms (17–20). 
Therefore, despite early data reporting an inflammatory effect 
of IFN-γ in the CNS during EAE development, accumulating 
evidence has also demonstrated a neuroprotective activity for 
IFN-γ in this disease.
Classical EAE is characterized by an ascending progressive 
paralysis dominated by inflammatory lesions in the white mat-
ter of the spinal cord and limited brain inflammation (2, 21). 
However, the absence of either IFN-γ or its receptor (IFNGR) 
leads to the development of atypical EAE symptoms such as head 
tilting, ataxia, dystonia, spasticity, and axial-rotation suggestive 
of brain-associated damage (19, 22–24). This atypical EAE is 
associated with greater encephalitogenicity of Th1 and Th17 cells 
and enhanced demyelination in the brainstem and cerebellum 
(19, 24). Even more, some studies have shown that IFN-γ may 
exert opposite effects in the brain and spinal cord determin-
ing the regional localization of lesions and inflammation in 
EAE. According to this evidence, IFN-γ induces inflammation 
in the spinal cord but protection in the brain (21, 25, 26). The 
mechanisms underlying these differential effects of IFN-γ may 
involve the regulation of the expression of specific chemokines in 
the brain versus spinal cord that restrain encephalitogenic T cell 
brain infiltration (19, 24, 25).
IFN-γ may also exert differential effects on the blood–brain 
barrier (BBB) and blood-spinal cord barrier (BSCB), resulting in 
opposite effects on their function and integrity. Supporting this 
hypothesis, atypical EAE symptoms were significantly ameliorated 
in mice that only expressed IFNGR in endothelial cells (EC-IFNGR 
mice). In these EC-IFNGR mice, inflammatory immune cell infil-
tration and demyelination were significantly inhibited in the brain 
but not in the spinal cord. In contrast to IFNGR-deficient mice, 
the functional integrity of the BBB was preserved in EC-IFNGR 
mice. This could be due to enhanced IFN-γ-induced claudin-5 
expression that resulted in increased paracellular tightness of brain 
endothelial cell cultures (27). Therefore, these results indicate that 
endothelial expression of IFNGR is necessary for maintaining BBB 
function and preventing atypical EAE and brain inflammation. 
Further analysis must be performed in order to establish differen-
tial effects of IFN-γ on the BSCB.
iFn-γ AnD CnS-ReSiDenT CeLLS
There are two groups of glial cells in the CNS: the macroglia, 
including astrocytes, oligodendrocytes, and ependymal cells, and 
the microglia. Several studies support the notion that glial cells 
not only provide functional support to neurons nor are they only 
a target of autoimmune injury, but are also active players in the 
development and progression of MS and EAE. Indeed, studies 
using an adoptive transfer EAE model have suggested that preven-
tion of atypical EAE by IFN-γ is dependent on IFN-γ signaling 
not only in encephalitogenic T cells but also in glial cells (19, 25). 
Below, we will review the opposite effects of IFN-γ on glial cells 
and neurons, highlighting its less known protective functions and 
the mechanisms whereby IFN-γ is able to exert neuroprotection 
(Figure 1).
Oligodendrocytes
Oligodendrocytes are CNS-resident myelin-producing cells 
and thus necessary for remyelination. Loss of oligodendrocytes, 
demyelination, and axonal damage are hallmarks of MS and EAE. 
Several in vitro studies have shown detrimental effects of IFN-γ 
on oligodendrocyte survival (28). Consistently, overexpression of 
IFN-γ in the CNS results in oligodendrocyte apoptosis and inhibi-
tion of myelination during development and after a demye-linating 
insult (15, 16, 29). However, when exposed to low levels of IFN-γ, 
oligodendrocytes were protected against oxidative stress and 
showed enhanced proteasome activity, two important processes 
preventing the accumulation of oxidized proteins, mitochondrial 
dysfunction and apoptosis (30). Furthermore, transgenic mice 
expressing low levels of IFN-γ were protected against chemically 
induced demyelination with cuprizone, and these animals did 
not show signs of oligodendroglial death, astrogliosis, or micro-
gliosis compared to wild-type mice exposed to the toxin (31). 
Interestingly, elevated levels of insulin-like growth factor (IGF)-1 
were detected in the CNS of these transgenic mice, which might 
contribute to the observed protective effects of IFN-γ, as IGF-1 has 
been demonstrated to inhibit oligodendrocyte apoptosis and pro-
mote myelination (31). Therefore, these results indicate that IFN-γ 
dose is critical in determining the survival of oligodendrocytes.
Those studies performed with transgenic mice have the limita-
tion that overexpression of IFN-γ was induced during myelin 
formation whereas EAE and MS occur when myelination has 
been established in adulthood. In order to overcome this pitfall, 
the same authors developed an elegant in  vivo experimental 
model that allowed temporally regulated delivery of IFN-γ to the 
CNS through a tetracycline-controllable system. IFN-γ delivery 
in the CNS that was first detected in the acute phase of EAE 
ameliorated disease severity and prevented oligodendrocyte loss, 
demyelination, and axonal damage. By contrast, delivery of this 
cytokine during the EAE remitting phase delayed disease recovery 
and inhibited remyelination (32). Interestingly, the effects of this 
cytokine in oligodendrocytes were mediated by the activation of 
protein kinase RNA-like endoplasmic reticulum kinase (PERK) 
FiGURe 1 | Dual role of iFn-γ on CnS-resident cells in eAe. IFN-γ in the CNS may facilitate helper T cell infiltration and neuroinflammation by inducing 
expression of VCAM-1, ICAM-1, and the chemokines CCL2, CXCL9, and CXCL10 in astrocytes located in close proximity to the BBB. Despite this, IFN-γ promotes 
BBB integrity by enhancing the expression and membrane distribution of claudin-5, in turn increasing tightness and ameliorating EAE severity. In microglia, IFN-γ 
differentially causes pathogenic cytotoxicity or neuroprotection and apoptosis depending on dose. Low-dose IFN-γ can induce tolerogenic microglia, while high 
doses result in increased expression of MHC class II protein and co-stimulatory molecules, leading to encephalitogenic T cell activation. TNF-α expression is 
upregulated by IFN-γ in microglia and inhibits their neuroprotective properties. In contrast, IFN-γ upregulates microglial IDO expression limiting T cell proliferation and 
inducing Fas and FasL expression favoring increased T cell apoptosis. IFN-γ also induces IL-18bp expression in microglia which inhibits the proinflammatory actions 
of IL-18 inhibiting EAE. In neurons, IFN-γ can induce B7 co-stimulatory molecules and TGF-β expression, promoting a Treg cell population that suppresses EAE. In 
oligodendrocytes, the effect of IFN-γ depends on both dose and the level of ER stress. By inducing expression of MHC molecules and other immune proteins, IFN-γ 
overloads the stress response in actively myelinating oligodendrocytes causing cell death, whereas a moderate stress response induced by low dose of IFN-γ on 
steady-state oligodendrocytes decreases apoptosis and increases IGF-1 levels in the CNS promoting remyelination of post-neuroinflammatory damage.
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and the phosphorylation of the α-subunit of eukaryotic translation 
initiation factor 2 (eIF2a), factors associated with the endoplasmic 
reticulum (ER) stress response (29, 32). The authors explained these 
apparently contradictory results proposing a dual role of IFN-γ on 
oligodendrocyte survival depending on their developmental stage 
and cellular stress (33, 34). According to this model, during the 
active process of myelination such as CNS development or remyeli-
nation (i.e., EAE remission), IFN-γ causes an overloaded ER stress 
response by increasing expression of MHC molecules and other 
inflammatory proteins in oligodendrocytes with already elevated 
function and preventing atypical EAE and brain inflammation. 
Further analysis must be performed in order to establish differen-
tial effects of IFN-γ on the BSCB.
iFn-γ AnD CnS-ReSiDenT CeLLS
There are two groups of glial cells in the CNS: the macroglia, 
including astrocytes, oligodendrocytes, and ependymal cells, and 
the microglia. Several studies support the notion that glial cells 
not only provide functional support to neurons nor are they only 
a target of autoimmune injury, but are also active players in the 
development and progression of MS and EAE. Indeed, studies 
using an adoptive transfer EAE model have suggested that preven-
tion of atypical EAE by IFN-γ is dependent on IFN-γ signaling 
not only in encephalitogenic T cells but also in glial cells (19, 25). 
Below, we will review the opposite effects of IFN-γ on glial cells 
and neurons, highlighting its less known protective functions and 
the mechanisms whereby IFN-γ is able to exert neuroprotection 
(Figure 1).
Oligodendrocytes
Oligodendrocytes are CNS-resident myelin-producing cells 
and thus necessary for remyelination. Loss of oligodendrocytes, 
demyelination, and axonal damage are hallmarks of MS and EAE. 
Several in vitro studies have shown detrimental effects of IFN-γ 
on oligodendrocyte survival (28). Consistently, overexpression of 
IFN-γ in the CNS results in oligodendrocyte apoptosis and inhibi-
tion of myelination during development and after a demye-linating 
insult (15, 16, 29). However, when exposed to low levels of IFN-γ, 
oligodendrocytes were protected against oxidative stress and 
showed enhanced proteasome activity, two important processes 
preventing the accumulation of oxidized proteins, mitochondrial 
dysfunction and apoptosis (30). Furthermore, transgenic mice 
expressing low levels of IFN-γ were protected against chemically 
induced demyelination with cuprizone, and these animals did 
not show signs of oligodendroglial death, astrogliosis, or micro-
gliosis compared to wild-type mice exposed to the toxin (31). 
Interestingly, elevated levels of insulin-like growth factor (IGF)-1 
were detected in the CNS of these transgenic mice, which might 
contribute to the observed protective effects of IFN-γ, as IGF-1 has 
been demonstrated to inhibit oligodendrocyte apoptosis and pro-
mote myelination (31). Therefore, these results indicate that IFN-γ 
dose is critical in determining the survival of oligodendrocytes.
Those studies performed with transgenic mice have the limita-
tion that overexpression of IFN-γ was induced during myelin 
formation whereas EAE and MS occur when myelination has 
been established in adulthood. In order to overcome this pitfall, 
the same authors developed an elegant in  vivo experimental 
model that allowed temporally regulated delivery of IFN-γ to the 
CNS through a tetracycline-controllable system. IFN-γ delivery 
in the CNS that was first detected in the acute phase of EAE 
ameliorated disease severity and prevented oligodendrocyte loss, 
demyelination, and axonal damage. By contrast, delivery of this 
cytokine during the EAE remitting phase delayed disease recovery 
and inhibited remyelination (32). Interestingly, the effects of this 
cytokine in oligodendrocytes were mediated by the activation of 
protein kinase RNA-like endoplasmic reticulum kinase (PERK) 
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BBB integrity by enhancing the expression and membrane distribution of claudin-5, in turn increasing tightness and ameliorating EAE severity. In microglia, IFN-γ 
differentially causes pathogenic cytotoxicity or neuroprotection and apoptosis depending on dose. Low-dose IFN-γ can induce tolerogenic microglia, while high 
doses result in increased expression of MHC class II protein and co-stimulatory molecules, leading to encephalitogenic T cell activation. TNF-α expression is 
upregulated by IFN-γ in microglia and inhibits their neuroprotective properties. In contrast, IFN-γ upregulates microglial IDO expression limiting T cell proliferation and 
inducing Fas and FasL expression favoring increased T cell apoptosis. IFN-γ also induces IL-18bp expression in microglia which inhibits the proinflammatory actions 
of IL-18 inhibiting EAE. In neurons, IFN-γ can induce B7 co-stimulatory molecules and TGF-β expression, promoting a Treg cell population that suppresses EAE. In 
oligodendrocytes, the effect of IFN-γ depends on both dose and the level of ER stress. By inducing expression of MHC molecules and other immune proteins, IFN-γ 
overloads the stress response in actively myelinating oligodendrocytes causing cell death, whereas a moderate stress response induced by low dose of IFN-γ on 
steady-state oligodendrocytes decreases apoptosis and increases IGF-1 levels in the CNS promoting remyelination of post-neuroinflammatory damage.
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ER stress, resulting in apoptotic program activation. Conversely, 
mature oligodendrocytes in adult mice produce significantly lower 
levels of membrane to maintain myelin homeostasis (i.e., acute 
EAE). In this case, IFN-γ would induce a moderate and protec-
tive ER stress response leading to oligodendrocyte survival and 
remyelination (33–35). Further investigations have determined 
that protection of oligodendrocytes in EAE may be mediated 
through Janus kinase (JAK) and the transcription factor signal 
transducer and activator of transcription (STAT)-1 signaling, as 
overexpression of the suppressor of cytokine signal (SOCS)-1, a 
competitive inhibitor of the IFN-γ-induced JAK/STAT-1 signaling 
pathway resulted in early EAE onset, enhanced inflammation, and 
oligodendrocyte apoptosis (30). Instead, the signal transduction 
pathway activating the transcription factor interferon regulatory 
factor (IRF)-1 would play a proinflammatory role in oligodendro-
cytes during EAE progression (36).
Microglia
Microglia comprise 10–20% of all glial cells and are considered 
the immune sentinels of the CNS (37). They develop a broad and 
versatile range of functions involved in inflammation, immu-
nomodulation, and promotion of neural repair that can be medi-
ated in part by IFN-γ (38, 39). IFN-γ potentiates the phagocytic 
activity of microglia (40) and induces the expression of MHC class 
II and co-stimulatory molecules. This enables them to function as 
antigen-presenting cells (APCs) for infiltrating myelin-specific T 
cells leading to inflammation and demyelination (41–45).
During neuroinflammation, different subtypes of microglia 
can be distinguished according to their activation status. M1 
microglia are primarily associated with an inflammatory 
phenotype and EAE initiation, while M2 microglia play an anti-
inflammatory role and participate in tissue repair and remodeling 
associated with EAE recovery (5, 46). Despite being a potent acti-
vator of microglia and their polarization toward M1, IFN-γ can, 
at least in part, regulate the dual activity of microglia, modulating 
both pathogenic and regenerative processes (40, 47–49). How can 
IFN-γ lead these opposing roles?.
Evidence suggests that IFN-γ dose constitutes a fine-tune 
mechanism of regulation determining the balance between 
inflammatory and anti-inflammatory microglia. IFN-γ along 
with neuroantigen can determine an effector or regulatory helper 
T cell response modulating the activation state of microglia in 
a dose-dependent manner (48). Myelin oligodendrocyte glyco-
protein (MOG)-specific CD4+ T cells co-cultured with microglia 
that were pre-activated with a high dose of IFN-γ and MOG 
peptide were primarily differentiated toward CD4+CD25+FoxP3− 
effector T cells. Instead, microglia primed with a low dose of 
both IFN-γ and neuroantigen induced the expansion of stable 
CD4+CD25+FoxP3+ regulatory T cells (Tregs) capable of sup-
pressing EAE after adoptive transfer (48). Furthermore, low 
concentrations of IFN-γ enabled microglia to perform neuro-
protective functions such as clearance of glutamate, neuronal 
survival, neurogenesis, and, to a lesser extent, oligodendrogen-
esis in response to CNS insult (50–52). Remarkably, EAE disease 
onset was significantly delayed in mice that were stereotaxically 
injected with microglia activated in vitro by a low dose of IFN-γ 
into the cerebral ventricles 7 days after immunization (53). By 
contrast, high concentrations of IFN-γ rendered microglia 
cytotoxic and impaired their neuroprotective activities (50–53). 
Interestingly, the dose-dependent paradoxical effects of IFN-γ 
may be mediated by microglial production of tumor necrosis 
factor (TNF)-α. Neutralization of TNF-α, whose expression is 
upregulated in IFN-γ-activated microglia, boosted both the 
neurogenesis and oligodendrogenesis induced by microglia 
activated with low-dose IFN-γ, whereas the addition of TNF-α to 
similar cell cultures prevented these cell renewal processes (52). 
Thus, low levels of IFN-γ induce beneficial effects on microglia, 
which are counteracted by the microglial production of TNF-α 
in response to increasing levels of IFN-γ.
On the other hand, IFN-γ can induce several self-limiting 
negative feedback mechanisms to restrain the magnitude and 
duration of its proinflammatory effects on microglia and to 
provide CNS protection. For example, IFN-γ induces mRNA 
expression of SOCS-1 which antagonizes IFN-γ-induced STAT-1 
activation (54). Indeed, overexpression of SOCS-1 inhibited IFN-
γ-induced expression of MHC class II and CD40 in microglia 
by inhibiting STAT-1-mediated expression of the class II trans-
activator (CIITA) transcription factor (54, 55). Furthermore, 
IFN-γ induced microglial cell death through the upregulation of 
apoptotic proteins, especially bcl-2-associated X protein (Bax), 
in EAE (56). This process was only observed in the advanced 
stage of EAE, suggesting a disease stage-specific role of IFN-γ 
on microglia in EAE, and likely MS. In fact, the activation and 
subsequent death of microglia induced by IFN-γ was proposed as 
a possible mechanism underlying MS relapse and remission (56).
Another important regulatory mechanism of IFN-γ is the 
suppression of T cell functions by localized catabolism of the 
aminoacid tryptophan, which is essential for cell growth and func-
tioning. Indoleamine-2,3-dioxygenase (IDO), whose expression 
in microglia is upregulated by the IFN-γ-induced STAT-1 and 
phosphatidylinositol 3-kinase (PI3K) signaling pathways (57), 
catabolizes tryptophan to kynurenine, and has been shown to play 
a protective role in EAE (58). Microglial IDO expression, induced 
by IFN-γ, reduced extracellular tryptophan and increased kynure-
nine which suppressed the proliferation of myelin-specific T cells 
and inhibited production of proinflammatory Th1 cytokines (59). 
In addition, tryptophan deprivation made T cells more susceptible 
to apoptosis through Fas-Fas ligand (FasL)-mediated signaling 
(60), whose expression can be induced in microglia by IFN-γ 
(61), enabling them with an additional protective mechanism by 
facilitating apoptosis of myelin-specific T cells.
Additionally, IFN-γ establishes a regulatory feedback limit-
ing the inflammatory activity of interleukin (IL)-18, a member 
of the IL-1 family produced by microglia that synergizes with 
IL-12 to induce Th1 polarization and IFN-γ production. IL-18 
is upregulated during EAE (62) and its neutralization inhibited 
EAE (63). In turn, IFN-γ induced the expression of IL-18 bind-
ing protein (IL-18bp), an endogenous inhibitor of IL-18, in 
CNS-resident microglia and infiltrating macrophages during 
EAE (64). Interestingly, augmented IL-18bp expression in the 
CNS mediated by an adenoviral vector, blocked the induction of 
Th17 cells, but not Th1 cells, in the CNS and significantly reduced 
the incidence and severity of EAE (64). Therefore, these results 
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suggest that IFN-γ-dependent IL-18bp production in microglia 
might regulate the balance between the Th1 and Th17 responses 
during autoimmune neuroinflammation.
Astrocytes
Astrocytes are the most abundant glial cell population and are 
essential for brain homeostasis and neuronal function. They play 
a major role in maintaining both the structure and functional 
integrity of the BBB, develop metabolic functions, and seclude 
damaged areas in the CNS. Astrocytes also exhibit a variety 
of immune functions whereby they may both stimulate and 
restrain neuroinflammation (65–68). Although the capability 
of astrocytes to function as APCs in  vivo is still controversial, 
some investigators have identified astrocytes expressing MHC 
class II molecules (69), co-stimulatory B7 molecules (70), and 
intercellular adhesion molecule (ICAM)-1 (71) at the edges of 
active MS lesions. The expression of these antigen-presenting 
molecules in astrocytes is upregulated by IFN-γ both in vivo and 
in vitro (12). In line with these results, astrocytes exposed to IFN-
γ in vitro can induce proliferation of myelin-specific T cells and 
Th1 differentiation (66, 68). Importantly, CD4+ T cells activated 
by astrocytes treated with IFN-γ and pulsed with myelin protein 
were able to induce EAE by adoptive transfer (72). In addition, 
IFN-γ upregulated expression of ICAM-1 and vascular cell adhe-
sion molecule (VCAM)-1 on primary astrocytes (72, 73), which 
might have a direct impact on the extravasation of T cells into the 
CNS considering the close apposition of astrocyte foot processes 
to the microvascular endothelium of the BBB.
IFN-γ signaling in astrocytes also plays an important role in 
triggering expression of a wide range of chemokines involved in 
the recruitment of inflammatory cells to the CNS in EAE and MS. 
At the edges of demyelinating MS lesions, astrocytes expressed 
CCL2, CXCL10, and their respective receptors CCR2 and CXCR3 
(74, 75). In EAE, CCL2 and CXCL10 were localized predomi-
nantly in astrocytes surrounding inflammatory lesions (76–78) 
and their expression was abolished in IFNGR-deficient mice (76). 
In  vitro studies have confirmed that both human and murine 
astrocytes are induced by IFN-γ to produce CCL2, CXCL9, and 
CXCL10 (79–81).
Selective silencing of IFN-γ signaling in astrocytes using a len-
tiviral vector significantly ameliorated both actively and passively 
induced EAE (82). Surprisingly, purified astrocytes from spinal 
cord of these animals not only exhibited reduced expression 
of IFN-γ-inducible chemokines such as CXCL9, CXCL10, and 
CXCL11 but also inhibited expression of chemokines induced by 
IL-17 signaling such as CXCL1, CXCL2, and CCL20 (82). These 
results were confirmed in vitro by analyzing astrocytes deficient 
in IFNGR and suggest that IFN-γ signaling is the common path-
way in both Th1 and Th17 cell-mediated EAE (82). In contrast 
to results depicted in astrocytes, the authors of this study found 
that selective blocking of IFN-γ signaling in microglia resulted 
in more severe EAE progression that was associated with sig-
nificantly enhanced CNS inflammatory infiltration. In addition, 
IFN-γ signaling restricted microglia proliferation (82). Together, 
these results suggest that IFN-γ would exert opposing roles on 
two different CNS-resident cell types in EAE: inflammatory on 
astrocytes and protective on microglia.
However, another study using transgenic mice expressing a 
signaling deficient dominant-negative IFNGR1 specifically on 
astrocytes reached opposite conclusions when analyzing EAE 
progression (83). Compared to wild-type mice, these animals did 
not show alteration in the incidence, disease onset, or initiation 
of clinical symptoms. Instead, during the transition from acute to 
chronic disease, the clinical score and mortality were significantly 
increased, suggesting that IFN-γ signaling in astrocytes provides 
disease stage-specific protection (83). Different methodological 
strategies used to ablate IFN-γ signaling might explain the dis-
crepant results found between these two studies (82, 83). A 
posterior study demonstrated that persistent CNS inflammation 
and progressive disability observed in these mice lacking IFN-γ 
signaling in astrocytes was associated with elevated expression of 
IL-6 and sustained proliferation and activation of microglia (84). 
Taken together, these results indicate that IFN-γ signaling plays 
an important role in controlling the proliferation of microglia 
during EAE either directly on microglia (82) or indirectly through 
astrocytes, (84) and highlight the crucial role of IFN-γ in the 
signaling network between astrocytes and microglia during EAE 
pathogenesis.
neurons
There is discrepant evidence regarding the relationship between 
neurons and IFN-γ, mainly described in the non-inflammatory 
brain, with both protective and detrimental effects (3, 9, 85, 86). 
In EAE, it has been observed that treatment with nerve growth 
factor (NGF), a well-known neural factor involved in neuron 
survival, decreased disease severity, and increased IFNGR 
expression in spinal cord neurons (87). Even more, neurons were 
induced to express transforming growth factor (TGF)-β and B7 
molecules in response to IFN-γ  produced by encephalitogenic 
T cells. Remarkably, encephalitogenic T cell–neuron interaction 
induced higher neuron survival and promoted the conversion of 
encephalitogenic CD4+ T cells to functional CD4+CD25+TGF-
β+CTLA-4+ Tregs. The adoptive transfer of these converted Tregs 
suppressed EAE. Strikingly, the acquisition of this regulatory phe-
notype occurred in the CNS and was mediated by the production 
of IFN-γ and TNF-α by T cells (88).
COnCLUDinG ReMARKS
Despite several studies having reported an inflammatory effect of 
IFN-γ in the CNS during EAE development, accumulating data 
have also demonstrated that IFN-γ possesses neuroprotective 
activity in this disease. The recent evidence summarized in this 
review underscores the duality of IFN-γ on CNS-resident cells in 
EAE and provides different mechanisms whereby this cytokine 
exerts these opposing activities. In low doses, IFN-γ induces 
protection in both microglia and oligodendrocytes, while in high 
doses it induces disease worsening effects in both glial cell types. 
In astrocytes, the evidence reveals a primarily disease-promoting 
role for IFN-γ signaling, although it may be disease stage-specific. 
Interestingly, IFN-γ also exerts opposing roles in oligodendro-
cytes depending on the cell maturation status and cellular stress 
response. Importantly, these findings implicate that defects or 
fluctuations related to the expression of IFN-γ, its receptor, and/
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